DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fareston (Toremifene Citrate) - Published Studies

 
 



Fareston Related Published Studies

Well-designed clinical trials related to Fareston (Toremifene)

Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. [2013]

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2013]

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. [2011]

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]

Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. [2010.05.15]

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. [2010]

Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. [2009.11]

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. [2008.04.10]

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. [2008.01]

Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. [2007.11.01]

Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. [2006.09]

Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. [2006.06]

Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women. [2005.10]

Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. [2004.12]

Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. [2004.11]

[Activity of toremifene plus mitomycin, vindesin and cisplatin regimen in unresectable non-small cell lung cancer] [2004.08]

Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. [2004.07.15]

Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. [2003.10]

Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. [2003.06]

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. [2001.04.06]

Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. [2001.01]

Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. [2000.10.15]

Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. [2000.10]

Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients. [2000.05.29]

Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients. [2000]

Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. [1999.11]

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. [1998.12]

Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. [1998.04]

A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. [1997.09]

Evolving role of toremifene in the adjuvant setting. [1997.05]

High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. [1997.05]

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. [1997]

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. [1996.02]

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. [1995.12]

Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. [1995.11]

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. [1995.10]

Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. [1993.04]

Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial. [1993]

Phase I study of toremifene in patients with advanced cancer. [1991.11]

Phase III studies of toremifene in metastatic breast cancer. [1990.08]

Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. [1990.08]

Hormonal effects of toremifene in breast cancer patients. [1990.06.22]

Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. [1990]

Well-designed clinical trials possibly related to Fareston (Toremifene)

Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. [2011.08]

Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. [2011]

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. [2009.03]

Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. [2008.09.10]

Body mass index influences palpability but not stage of breast cancer at diagnosis. [2007.06]

Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53. [2006.02]

A double-blind randomized controlled trial of toremifen therapy for mastalgia. [2006.01]

Drug resistance in chemotherapy for breast cancer. [2005.11]

Urogenital effects of selective estrogen receptor modulators: a systematic review. [2005.09]

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. [2001.04.20]

Antiestrogens reduce plasma levels of endothelin-1 without affecting nitrate levels in breast cancer patients. [2000.02]

[Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women] [1997]

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. [1997]

Other research related to Fareston (Toremifene)

Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials. [2014]

Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer. [2014]

Toremifene versus tamoxifen for advanced breast cancer. [2012]

Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis. [2012]

Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study. [2011.08]

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. [2011.08]

[A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer]. [2011.07]

Diethylenetriamine pentaacetic acid derivative of toremifene and in vitro evaluation in human breast cancer cell line MCF-7. [2011.02]

[A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy]. [2011.01]

Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study. [2011]

[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer]. [2010.11]

Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. [2010.10]

Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging. [2010.07]

[Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients] [2010.02]

Toremifene use does not alter serum inhibin A and B levels during mid-luteal phase in women with premenstrual mastalgia. [2010.02]

Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010]

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. [2010]

[A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy] [2009.12]

[A case of advanced breast cancer with skin ulceration successfully treated with paclitaxel and toremifene therapy] [2009.11]

[Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors] [2009.09]

Breast Magnetic Resonance Imaging Findings in Women Treated with Toremifene for Premenstrual Mastalgia. [2009.08.27]

Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer. [2009.08]

[Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment] [2009.06]

[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene] [2009.04]

Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats. [2009.02]

Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer. [2009]

[Recurrence of skin and lymph nodes from asynchronous breast cancer successfully treated with paclitaxel and toremifene therapy--a case report] [2008.11]

Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. [2008.01]

The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. [2007.10]

[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy] [2007.07]

The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model. [2007.07]

The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. [2007.04.03]

[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene] [2007.03]

[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine] [2007.03]

DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene. [2007.02]

DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene. [2007.02]

[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel] [2007.01]

Toremifene: an evaluation of its safety profile. [2006.04]

Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene. [2006.03]

Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. [2006.03]

[Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer] [2005.10]

Stabilization and regression of a recurrent desmoid tumor with the antiestrogen toremifene. [2005.08]

A highly vascular intracranial solitary fibrous tumor treated with radiotherapy and toremifene: case report. [2005.06]

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. [2005.04]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017